Omamah Eid

Omamah Eid

King Saud University, Riyadh, Ar Riyāḑ, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FAFai Alkathiri
Fai Alkathiri
OEOmamah Eid
Omamah Eid
NANjoud Altuwaijri
Njoud Altuwaijri
RARihaf Alfaraj
Rihaf Alfaraj
EEEram Eltahir
Eram Eltahir
GGGhadah Ghadah
Ghadah Ghadah
Background: Furosemide is a loop diuretic used extensively to treat adult and pediatric patients. In some hospitals, furosemide oral liquids are not available in stock, thus necessitating the extemporaneous preparation of the drug. This study evaluates the stability of on-the-spot formulations of furosemide oral suspensions from crushed tablets evaluated in various vehicles: Dextrose 50%, Dextrose 70%, Ora-Sweet, and Ora-Plus over 60 days. This examination was prompted by the frequent shortage of certain excipients in the hospital, leading to the need to switch to Dextrose 50% or Dextrose 70% when Ora-Sweet and Ora-Plus are out of stock. Methods: The extemporaneous furosemide oral suspensions were prepared following the same compounding method used in the pharmacy. The suspensions were maintained at 4 °C in the refrigerator and assessed immediately and later, on days 7, 14, 30, and 60. The assessed parameters included visual appearance, redispersion time, sedimentation volume, and pH levels for stability analysis. We also examined the drug content, dissolution of the suspension, and microbiological stability. Results: Initial examinations indicated that Dextrose 50% and Ora-Plus maintained pH levels and stable appearances, while significant changes, mainly in appearance and redispersion time, indicated the instability of Dextrose 70%. Ora-Sweet showed fluctuations but stabilized by day 30. Dissolution studies demonstrated that Ora-Plus had dissolution characteristics superior to the other formulations, while Dextrose 50% showed declining dissolution percentages over time. Overall, the Ora-Plus vehicle showed superior stability (60 days), followed by Ora-Sweet (30 days), while Dextrose 70% and Dextrose 50% showed shorter stability durations of 14 and 7 days, respectively. The microbiological test results showed no microbial growth. Conclusions: This study demonstrates that the vehicle used in extemporaneous furosemide suspensions critically affects their stability and performance. Ora-Plus emerged as the most suitable vehicle, maintaining physical, chemical, and microbiological stability over 60 days, with consistent pH, redispersion, and dissolution behavior. Ora-Sweet showed intermediate stability (30 days), while Dextrose 50% and 70% exhibited early instability—7 and 14 days, respectively—marked by sedimentation, poor redispersibility, and declining drug release. These findings underscore the importance of vehicle selection and regular stability monitoring in compounded formulations to ensure therapeutic reliability and patient safety.

15 May 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
NANjoud Altuwaijri
Njoud Altuwaijri
FAFai Alkathiri
Fai Alkathiri
RARihaf Alfaraj
Rihaf Alfaraj
MAMohammed Aljallal
Mohammed Aljallal
AAAbrar S. Abduljawad
Abrar S. Abduljawad
FAFahad Ibrahim Al-Jenoobi
Fahad Ibrahim Al-Jenoobi
Background: Drug shortages represent a growing challenge to healthcare systems worldwide, affecting treatment continuity and patient outcomes. This study assessed the burden and perceived impact of drug shortages from both healthcare professionals’ and patients’ perspectives in a Saudi tertiary hospital. Methods: A cross-sectional survey was conducted in April 2025 at King Abdulaziz Medical City, Riyadh, Saudi Arabia. Convenience sampling was used to recruit healthcare professionals with at least two years of experience and adult outpatients. Structured questionnaires assessed shortage frequency, affected drug classes, perceived impacts, and management practices. The findings were descriptively analyzed and compared with the Saudi Food and Drug Authority (SFDA) national shortage data for the corresponding 12-month period. Results: A total of 230 healthcare professionals and 243 patients participated. Among healthcare professionals, 89.1% reported experiencing at least one drug shortage, with 38.3% encountering shortages more than ten times annually. Anti-infectives (36.5%) and analgesics (35.7%) were the most frequently reported classes. The most common response was prescribing alternative medications (77.4%), with 55.3% perceived as adequately effective and 30.8% as less effective. Delayed care was the most frequently reported consequence (44.0%). Among patients, 30.9% reported experiencing shortages, 46.7% reported some degree of health impact, and 28.1% incurred additional costs. Awareness and utilization of the SFDA reporting system were low in both groups. Comparison with SFDA data revealed discrepancies between hospital-reported and nationally reported shortages. Conclusions: Drug shortages were frequently reported and associated with perceived clinical and economic consequences. Gaps between hospital experiences and national reporting highlight limitations in current surveillance systems. Strengthening reporting mechanisms, communication, and supply chain coordination may improve the management of drug shortages.